Mavrilimumab produces rapid improvement in signs and symptoms of rheumatoid arthritis, measures of disability and patient-reported outcomes Sifalimumab meets primary endpoint of reduction in global disease activity score (SRI-4), and shows clinically important improvement in skin and joint symptoms, patient reported outcomes in patients with moderate/severe systemic lupus erythematosus
Benralizumab and tralokinumab data both show improvement in key measures of asthma control for patients with specific, severe forms of asthma Data underscore strength and breadth of AstraZeneca’s respiratory pipeline
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints
Idag tilldelas docent och överläkare Bengt Bergman, verksam vid Sahlgrenska universitetssjukhuset Göte¬borg, året SLUSG-stipendium 2014. Stipendiet har instiftats av AstraZeneca och Svenska Lungcancerstudiegruppen (SLUSG) och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.
First MedImmune oncology immunotherapy targeting the PD-L1/PD-1 pathway progresses into Phase III
Oscar Braun får 2014 års stipendium inom akuta koronara syndrom, utlyst av Svenska Cardiologföreningen och AstraZeneca. Idag tilldelas Oscar Braun, verksam vid avdelningen för kardiologi, Skånes universitetssjukhus i Lund ett forskningsstipendium på 120 000 kr. Stipendiet utlyses varje år för att stimulera klinisk forskning inom området akuta koronara syndrom.
The Board of AstraZeneca PLC ("AstraZeneca" or "the Company") is today publishing a presentation updating on the continued progress in executing its strategy, which centres on achieving scientific leadership, strengthening its growth platforms and returning to growth.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).
Intäkterna ökade 3% i fasta valutakurser (CER), med stöd av konsolideringen av hela diabetesfranchisen, som bidrog med 2 procentenheter av ökade intäkter, och starkt resultat inom de fem tillväxtplattformarna (Brilinta, diabetes, andningsvägar, tillväxtmarknader och Japan).
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K.
AstraZeneca’s IMED Biotech unit has launched a dedicated website to support an increasing range of open innovation programmes and to better facilitate research collaborations with academia, industry, NGOs and governments.
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes.
